Improving the evaluation of new cancer treatments: challenges and opportunities

被引：122

作者：

Rothenberg, ML ^{[1
]}

Carbone, DR ^{[1
]}

Johnson, DH ^{[1
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

来源：

NATURE REVIEWS CANCER | 2003年 / 3卷 / 04期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nrc1047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?.

引用

收藏

页码：303 / 309

页数：7

相关论文

共 42 条

[1]

AHMANN FR, 2001, P AN M AM SOC CLIN, V20, pA174

[2]

*BAY PHARM DIV, 2003, BAY HALTS CLIN TRIAL

[3] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].

Betensky, RA ;

Louis, DN ;

Cairncross, JG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499

[4]

BISSETT D, 2002, P AN M AM SOC CLIN, V21, pA296

[5] Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial [J].

Bramhall, SR ;

Hallissey, MT ;

Whiting, J ;

Scholefield, J ;

Tierney, G ;

Stuart, RC ;

Hawkins, RE ;

McCulloch, P ;

Maughan, T ;

Brown, PD ;

Baillet, M .

BRITISH JOURNAL OF CANCER, 2002, 86 (12) :1864-1870

[6] A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].

Bramhall, SR ;

Schulz, J ;

Nemunaitis, J ;

Brown, PD ;

Baillet, M ;

Buckels, JAC .

BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167

[7] Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial [J].

Bramhall, SR ;

Rosemurgy, A ;

Brown, PD ;

Bowry, C ;

Buckels, JAC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3447-3455

[8]

*BRIT BIOT PLC, 2003, RES MAR STUD 131 PAT

[9]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[10] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

← 1 2 3 4 5 →